



Step Therapy Edit Criteria Proposal

Drug/Drug Class Date: Prepared for: Prepared by:	Quinolone Ophthalmic Antibiotic Step Therapy Edit August 11, 2004 Missouri Medicaid Heritage Information Systems, Inc.			
☐ New Criteria		Revision of Exist	ing Criteria	
Executive Sum	nmary			
Purpose:	Control pharmacy program prescription costs by limiting the use of quinolone ophthalmic antibiotic drug products as first-line agents in the treatment of ophthalmic bacterial infections			
Why was this Issue Selected:	Ophthalmic antibiotic ointments, solutions, and suspensions account for 85,784 claims and \$1,652,244 in paid program services from April 2002 to March 2003. Prescription claims for quinolone products accounted for 23% of the total claim volume and 41% of the total paid amounts for all ophthalmic antibiotic products throughout that period. Utilizing reference drugs as first-line agents in the treatment of ophthalmic bacterial infections presents potential cost savings of \$1 million.			
Program- specific information:	 Drug Bacitracin Products Erythromycin Products Neomycin Products Quinolone Products Aminoglycoside Products Sulfa Products 	Claims 2,773 7,623 9,040 19,486 27,084 19,764 04/02 - 03/03	Expense \$42,014.53 \$53,965.08 \$149,887.59 \$669,988.62 \$555,254.60 \$180,895.61	
Setting & Population:	Medicaid FFS Patients.			
Type of Criteria:	☐ Increased risk of ADE☑ Appropriate Indications	⊠ Non-Prefer	Non-Preferred Agent □	
Data Sources:	☐ Only administrative databases	☐ Databases supplied	+ Prescriber-	

Approval Criteria

- Patient Diagnosis of:
 - 1. Cataract (ICD9 = 366, 743.3), or
 - 2. Glaucoma (ICD-9 = 365)
- Cataract Surgery In the past 45 days. CPT Codes:
 - 1. 66830
 - 2. 66820-66821
 - 3. 66982-66984
- Prescription Claim With Reference Ophthalmic Antibiotic Product
 - Demonstrates adequate trial on reference product
- Reference Drug Products:

Ophthalmic Antibiotic Ointments

Bacitracin Ophthalmic Ointment

Erythromycin Ophthalmic Ointment (Ilotycin®)

Bacitracin-Polymixin-Neomycin Ophthalmic Ointment (Neosporin®)

Sulfacetamide Sodium Ophthalmic Ointment (Bleph-10[®], Cetamide[®])

Bacitracin-Polymixin B Ophthalmic Ointment (Polysporin®)

Bacitracin-Polymixin-Neomycin-Hydrocortisone Ophthalmic Ointment (Cortisporin®)

Neomycin-Dexamethasone Phosphate Ophthalmic Ointment (Neo-Decadron®)

Neomycin-Polymixin B-Dexamethasone Ophthalmic Ointment (Maxitrol®)

Gentamicin Ophthalmic Ointment

Tobrex Ophthalmic Ointment

Tobramycin-Dexamethasone Ophthalmic Ointment (TobraDex®)

Ophthalmic Antibiotic Solutions and Suspensions

Gentamicin Ophthalmic Solution

Tobramycin Ophthalmic Solution (Tobrex®)

Sulfacetamide Sodium Ophthalmic Solution (Bleph-10[®], Sulf-10[®])

Neomycin-Dexamethasone Phosphate Ophthalmic Solution (Neo-Decadron®)

Neomycin-Polymixin B-Gramicidin Ophthalmic Solution (Neosporin®)

Neomycin-Polymixin B-Dexamethasone Ophthalmic Suspension (Maxitrol®)

Neomycin-Polymixin B-Hydrocortisone Ophthalmic Suspension (Cortisporin®)

Neomycin-Polymixin B-Prednisolone Acetate Ophthalmic Suspension (Poly-Pred®)

Gentamicin-Prednisolone Acetate Ophthalmic Suspension (Pred-G®)

Tobramycin-Dexamethasone Ophthalmic Suspension (TobraDex®)



Denial Criteria

- Prescription claim for non-reference ophthalmic antibiotic products with no claim history containing a reference ophthalmic antibiotic product within the past 45 days.
- Prescription claim for non-reference ophthalmic antibiotic products with no supporting ICD-9 or CPT codes.
- Non-Reference Ophthalmic Antibiotic Product

Ciprofloxacin HCI Ophthalmic Solution (Ciloxan[®])
Ciprofloxacin HCI Ophthalmic Ointment (Ciloxan[®])
Levofloxacin Ophthalmic Solution (Quixin[®])
Ofloxacin Ophthalmic Solution (Ocuflox[®])
Gatifloxacin Ophthalmic Solution (Zymar[®])
Moxifloxacin Ophthalmic Solution (Vigamox[®])
Norfloxacin Ophthalmic Solution (Chibroxin[®])

Required Documentation	on		
Appropriate Diagnosis MedWatch form:	X	Progress notes:	

Disposition of Edit

• **Denial:** Edit 681 "Step Therapy"

